To include your compound in the COVID-19 Resource Center, submit it here.

Short-circuiting DCs in atherosclerosis

A team of European researchers has identified a way to target proinflammatory dendritic cells that contribute to atherosclerotic plaques in mice.1 Carolus Therapeutics Inc. has a nonexclusive option to license the findings and believes the data may point to a new strategy for treating inflammation associated with cardiovascular and pulmonary disorders.

Multiple types of immune cells contribute to the proinflammatory pathology of atherosclerosis. Although macrophages are probably the best known cell type, other contributors include T

Read the full 752 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers